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ABSTRACT 
Objective: An attempt was made to develop sustained release matrix tablets of ibuprofen using HPMC (K4M, K15M & K100M) and eudragit (RS 100 
& RL 100) as release retardant polymers.  
Methods: The ibuprofen matrix tablets were prepared by direct compression method using lactose as a diluent. Nineteen formulations of different 
polymer percentages were formulated, (F1-F19 with 7.5%, 10%, 15%, 20%, 25%, 30% w/w).  
Results: The formulations were optimized on the basis of acceptable weight variation, thickness, hardness, % friability, % drug content and in vitro 
drug release. The in vitro release studies were performed using USP type II apparatus using 7.2 pH phosphate buffer as a dissolution medium, 
showed that optimized formulation F8 consisting of eudragit RL with 20% of the polymer was found to sustain the release of ibuprofen over a 
period of 12 h. The formulation exhibited highest correlation (R) value in case of Hixson-Crowell model and the release kinetic study proved that the 
formulation showed erosion process, and shown to follow zero order kinetics. 
Conclusion: It was concluded that eudragit RL can be used for the preparation of sustained release tablet of ibuprofen. 
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INTRODUCTION 
Over the past few decades, significant medical advances have been 
made in the area of drug delivery with the development of 
controlled release dosage forms. The primary benefit of a sustained 
release dosage form in comparison with conventional dosage form, 
maintains uniform drug plasma concentration over an extended 
period of time and hence the uniform therapeutic effect is achieved. 
To get a successfully sustained release product, the drug must be 
released from the dosage form at a predetermined rate and dissolve 
in the gastrointestinal fluids [1-4]. 
Ibuprofen (fig. 1) is a nonsteroidal anti-inflammatory agent used 
extensively in the treatment of rheumatoid arthritis, degenerative 
joint disease, osteoarthritis, ankylosing spondylitis, acute 
musculoskeletal disorders, and low back pain [2, 5]. Ibuprofen is 
belong to the group of propionic acid derivatives; it has a plasmatic 
half-life of 1.8-2.0 h; as a result, it has to be administered 3-6 times a 
day, making this drug a suitable candidate for a controlled or 
sustained release drug products that can potentially avoid drug 
release in upper position of the GI tract [6, 7].  
 
 
Fig. 1: Structure of ibuprofen 
 
The drug release rate from the dosage form is controlled mainly by 
the type and proportion of polymer used in the preparations [8]. 
Because of low costs and ease of fabrication, one of the most 
common approaches to get controlled release is to embed a drug in a 
hydrophobic matrix such as ethyl cellulose or hydrophilic matrix 
such as hydroxypropyl methyl cellulose (HPMC), eudragit, sodium 
carboxymethyl cellulose and sclero glucan [9]. Hydrophilic polymer 
matrix is widely used for formulating sustained release dosage form. 
HPMC is widely used hydrophilic polymer to prolong drug release 
due to its rapid hydration, good compression and gelling 
characteristics along with its ease of use, availability, and very low 
toxicity. It regulates the release of drug by controlling the swelling 
and cross-linking [8]. Poly acrylates and polymethacrylate, the 
glassy substances, are commonly referred to by the trade name 
eudragit. The commonly used eudragit for the preparation of 
controlled release formulations are eudragit L, eudragit RL, eudragit 
RS, eudragit RLPO and eudragit RSPO. Eudragit RL and eudragit RS, 
are ammonio methacrylate copolymers. The ammonium groups are 
present as salts and are mainly responsible for independent pH 
permeability of the polymers [1]. Abbaspour et al. (2008) used 
eudragit RS 30D & RL 30D with triethyl citrate to prepare SR pellets 
of ibuprofen and Ofokansi et al. 2013 formulated colon targetted 
ibuprofen tablets based on eudragit RL 100-chitosan inter 
polyelectrolyte complexes. However, to the best of our knowledge, 
there is no reported study on sustained release ibuprofen tablets 
with acrylic polymers (eudragit) and HPMC.  
Thus, this study was designed to investigate the formulation of 
sustained release tablets of ibuprofen and tested for controlled 
delivery of drug using hydrophilic matrix polymer such as HPMC K 
4M, HPMC K 100M, HPMC K 15M and polyacrylate polymers such as 
eudragit RL100 and eudragit RS100 to produce additive an 
inflammatory activity, results to reduce in frequency of dose of 
administration and to improve patient compliance.  
MATERIALS AND METHODS 
Materials 
Ibuprofen was procured from Yarrow chem. Products; Mumbai 
(India). Eudragit (RS 100, RL 100) and HPMC (K4M, K15M and 
K100M) were also procured from Yarrow chem. Products; Mumbai 
(India), lactose monohydrate, was procured from Finer Chemicals 
Ltd., Mumbai (India), talc was purchased from Loba chemei Pvt. Ltd., 
Mumbai (India). And magnesium stearate was purchased from Moly 
chem. Mumbai (India). 
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Methods 
Method for preparation of sustained release ibuprofen SR tablets 
Different tablet batch formulations (F1-F19) were prepared by 
direct compression method. Pure drug (ibuprofen) and polymers 
(eudragit RS 100 & RL 100 and HPMC K4M, K15M & K100M) were 
passed individually through #40 sieves and mixed well for 10 min in 
a mortar and pestle. To this blend, lactose (diluent) was added after 
passing through #40 sieves and mixed thoroughly for 5 min.  
This powder blend was lubricated with sufficient amounts of magnesium 
stearate and talc after passing through #60 sieves and then directly 
compressed into tablets using a single punch rotary tablet machine 
(Rimek tablet mini press, Ahmadabad) using 10 mm flat punches. Tablet 
hardness was kept within the range of 6-8 kg/cm2
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F 1 100 18.75 _ _ _ _ 128.25 2 1 250 
F2 100 25 _ _ _ _ 122 2 1 250 
F3 100 37.5 _ _ _ _ 109.5 2 1 250 
F4 100 50 _ _ _ _ 97 2 1 250 
F5 100 _ 18.75 _ _ _ 128.25 2 1 250 
F6 100 _ 25 _ _ _ 122 2 1 250 
F7 100 _ 37.5 _ _ _ 109.5 2 1 250 
F8 100 _ 50 _ _ _ 97 2 1 250 
F9 100 _ 62.5 _ _ _ 84.5 2 1 250 
F10 100 _ 75 _ _ _ 72 2 1 250 
F11 100 _ _ 18.75 _ _ 128.25 2 1 250 
F12 100 _ _ 25 _ _ 122 2 1 250 
F13 100 _ _ 37.5 _ _ 109.5 2 1 250 
F14 100 _ _ _ 18.75 _ 128.25 2 1 250 
F15 100 _ _ _ 25 _ 122 2 1 250 
F16 100 _ _ _ 37.5 _ 109.5 2 1 250 
F17 100 _ _ _ _ 18.75 128.25 2 1 250 
F18 100 _ _ _ _ 25 122 2 1 250 
F19 100 _ _ _ _ 37.5 109.5 2 1 250 
Each batch contains 50 tablets. 
 
Micromeritic properties of formulation blends 
Angle of repose  
The angle of repose is the angle formed by the horizontal base of the 
bench surface and the edge of a cone-like pile of powder. Funnel used 
was a stainless steel funnel and the size of the orifice was 10 mm and 
the height from the beginning of funnel to end of the orifice was 11 
mm. The funnel was fixed in place, 4 cm above the bench surface. 
After the cone from 5 g of the sample had been built, the height of 
the powder forming the cone (h) and the radius (r) of the base were 





θ = Tan−1 h
r
                        ----------------- (1) 
Bulk density  
Apparent bulk density (ρ0) was determined by weighing accurately 
25 g of powder (M), which was previously passed through #40 
sieves and transferred in 100 ml graduated cylinder. Carefully level 
the powder without compacting, and read the unsettled apparent 
volume (V0
Bulk density �ρ0� =
M
V0
                    --------------- (2) 
) [11]. Calculate the apparent bulk density in g/ml by the 
following formula:  
Tapped density  
Weigh accurately 25 g of powder (M), which was previously passed 
through #40 sieves and transfer in 100 ml graduated cylinder. Then 
mechanically tap the cylinder containing the sample by raising the 
cylinder and allowing it to drop under its own weight using 
mechanically tapped density tester that provides a fixed drop of 
14±2 mm at a nominal rate of 300 drops per minute. Tap the 
cylinder for 500 times initially and measure the tapped volume (V1) 
to the nearest graduated units, repeat the tapping an additional 750 
times and measure the tapped volume (V2) to the nearest graduated 
units. If the difference between the two volumes is less than 2% then 
final the volume (Vf
Tapped density = M
Vf
------------------ (3) 
) [11]. Calculate the tapped density in g/ml by 
the following formula:  
 
Compressibility index or Carr’s index (CI)  
Compressibility index or Carr’s index is measured using the values 
of bulk density and tapped density [12]. The following equation is 
used to find the Carr’s index:  
CI = Tapped density−Bulk density
Tapped density
× 100-------- (4) 
 
Table 2: Range of Carr’s index and Hausner’s ratio and flow 
character according to I. P 
Carr’s index Flow character Hausner’s ratio 
<10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very very poor >1.60 
 
Hausner’s ratio  
It indicates the flow properties of the powder and the ratio of tapped 
density to the bulk density of the powder or granules [12]. It can be 
measured as:  
Hausner′s ratio = Tapped density
Bulk density
                 ------------- (5) 
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Evaluation of compressed tablets 
Thickness  
The thickness of the matrix tablets was determined using vernier 
caliper (Mitutoyo, New Delhi, India) and the results were expressed 
as mean values of 3 determinations, with standard deviations. 
Weight uniformity test  
Twenty tablets from each batch were weighed using an electronic 
balance (Infra instruments Pvt. Ltd, Chennai; Model-IN 201 L EC) 
together and individually, and the mean weight and % deviations 
were calculated according to USP [13].  
Hardness measurement  
For each formulation, the hardness of 5 tablets (according to IP) [14] 
was determined using an electronic hardness tester (Monsanto type, 
Dolphin). The mean crushing strength (hardness) was determined, 
and the data are presented in the table 4. 
Friability [12, 16] 
Ten tablets (according to IP) [14] were randomly selected from each 
batch and weighed. The tablets were set to rotate at 25 rpm for 4 
min in a friabilitor (Roche Friabilator, DBK instruments). Tablets 
were dusted and reweighed. Compressed tablets should not lose 
more than 1% of their weight. The friability was calculated 
according to the formula:  
% Friability = Initial weight−Final weight
Initial weight
× 100      -------------- (6) 
Drug content 
Accurately weighed the quantity of the tablet powder equivalent to 
100 mg of the drug was transferred to 100 ml volumetric flask. 50 
ml of buffer solution of pH-7.2 was added. Mix with the aid of 
ultrasound for 10 min, and then the volume was made up to 100 ml 
with the same buffer solution, mixed solution was filtered through 
0.45 μm membrane (Nunc, New Delhi, India) 5 ml of the filtrate was 
diluted to 100 ml with same buffer solution and examined under U. 
V Spectrophotometer (Agilent Technologies, Germany; Model-Cary 
60 UV-Vis) at 220 nm. 
In vitro release studies  
In vitro release of ibuprofen from the tablets was studied using USP 
Type II dissolution apparatus (Disso 2000, Labindia) in pH 7.2 
phosphate buffer at 37±1 °C. The volume of the dissolution medium 
was 900 ml, and the stirring speed was set at 50 rpm. At 
predetermined time intervals, 5 ml of sample was withdrawn and 
replaced with fresh pre-heated (maintained 37±1 °C) dissolution 
media. Samples were filtered through 0.45-μ membrane (Nunc, New 
Delhi, India) and analyzed after suitable dilution. All dissolution 
studies were carried out in triplicate, and the mean values were 
plotted versus time with SDs of less than 3, indicating the 
reproducibility of the results.  
RESULTS AND DISCUSSION 
Ibuprofen is a non-steroidal anti-inflammatory agent belonging to 
the group of propanoic acid derivatives. It shows a plasmatic half-life 
of 1.8-2.0 h; as a result it has to be administered 3 to 6 times a day, 
making this drug a suitable candidate for a controlled/sustained 
release formulation [6]. In this present study hydrophilic 
polyacrylate polymer such as eudragit (RS 100 & RL 100) and the 
hydrophilic polymer of HPMC in different grades like HPMC K4M, 
K100M & K15M have been employed to formulate sustained release 
tablets of ibuprofen in different batches. 
The sustained release tablets of ibuprofen were prepared (19 
batches) by direct compression method according to the formulae 
given in table 1. Direct compression is one of the techniques which 
require the incorporation of directly compressible diluents into the 
formulation. It does not require the use of water or heat the formula 
and is the ideal method for moisture and heat liable medications. 
This is a process of compressing mixed powders into tablets without 
the need of intermediate granulating step. This technique involves 
conventional equipment, commonly available excipients and a 
limited number of processing steps. High doses can also be 
accommodated, and the final weight of tablet can easily exceed than 
that of other methods. The pre-compression powder blends of 
different batches were evaluated for angle of repose, bulk density, 
tapped density, compressibility index and Hausner’s ratio & the 
values are in table 3. The formulations F3, F9, F11, F16, F18 and F19 
showed good flow property (26.12-29.0), but other formulations (F1, 
F2, F4, F5, F6, F7, F8, F10, F12, F13, F14, F15, F17) showed excellent flow 
property (21.02-25.68). The compressibility index ranged from 8.47 to 
14.97. Bulk densities of powder blend contain HPMC polymer (F11-F19) 
was found to be quite higher than those of other powders. This may be 
due to the presence of more fines in the blend. In addition, the density 
may influence compressibility, dissolution, and other properties [15-17]. 
All these results indicate that the powder possessed satisfactory flow 
properties, compressibility, and Hausner’s ratio. 
 




repose ( °) 
Bulk density (g/ml) Tapped density (g/ml) Compressibility index (%) Hausner’s 
ratio 
F1 21.02±1.08 0.367±1.04 0.401±1.10 8.47±1.11 1.09±1.14 
F2 24.52±1.05 0.283±1.1 0.325±1.11  12.92±1.04 1.14±1.13 
F3 27.64±1.18 0.354±1.03 0.402±1.09 11.94±1.08 1.13±1.23 
F4 23.69±1.11 0.345±1.04 0.412±1.08 14.07±1.11 1.13±1.19 
F5 22.89±1.05 0.298±1.05 0.348±1.14 12.86±1.14 1.16±1.21 
F6 25.64±1.20 0.289±1.02 0.325±1.20 11.07±1.07 1.12±1.11 
F7 23.98±1.31 0.393±1.09 0.454±1.09 13.43±1.11 1.15±1.12 
F8 23.54±1.25 0.391±1.04 0.451±1.23 13.30±1.09 1.15±1.32 
F9 28.12±1.24 0.386±1.16 0.454±1.26 14.97±1.11 1.17±1.05 
F10 21.58±1.18 0.352±1.32 0.419±1.21 12.90±1.15 1.14±1.32 
F11 26.94±1.05 0.464±1.21 0.524±1.10 11.45±1.09 1.12±1.21 
F12 23.84±1.07 0.394±1.22 0.454±1.08 13.21±1.08 1.15±1.49 
F13 22.58±1.06 0.382±1.05 0.435±1.06 12.18±1.06 1.13±1.20 
F14 23.94±1.03 0.389±1.07 0.439±1.14 11.38±1.11 1.12±1.12 
F15 25.68±1.11 0.512±1.04 0.582±1.09 12.02±1.23 1.13±1.41 
F16 26.12±1.06 0.499±1.08 0.569±1.07 12.30±1.25 1.14±1.56 
F17 23.02±1.22 0.502±1.10 0.581±1.15 13.59±1.36 1.15±1.63 
F18 29.00±1.18 0.359±1.04 0.410±1.09 12.43±1.28 1.14±1.72 
F19 28.48±1.18 0.444±1.22 0.512±1.18 13.28±1.31 1.15±1.35 
 *All values are expressed as mean±SD, n=3 
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The tablets of different formulations were subjected to various 
evaluation tests, such as thickness, uniformity of weight, drug 
content, hardness and friability values in table 4 and in vitro 
dissolution test (fig. 2, fig. 3). The thickness of tablets ranged from 
5.3 to 5.6 mm. Tablet thickness is consistent batch to batch or within 
a batch only if the tablet granulation or powder blend is adequately 
consistent in particle size and size distribution, if the punch tooling 
is of consistent length, and if the tablet press is clean and in good 
working order. Tablet thickness should be controlled within a±5% 
variation of a standard value; thickness must be controlled to facilitate 
packaging. The average weight of 20 tablets from each formula was 
ranged from 245.11 to 255.09 mg. The pharmacopeial limit for the 
percentage deviation for tablets of more than 250 mg is ± 5%. The 
average percentage deviation of all tablet formulations was to be 
within the above limit, and hence, all formulations passed the test 
for uniformity of weight as per official requirements [14]. Drug 
content was found to be uniform among different batches of the 
tablets and ranged from 95.60 to 101%. Good uniformity in drug 
content was found among different batches of the tablets, and the 
percentage of drug content was more than 95%. The hardness and 
friability of the tablets of all batches ranged from 6-8 kg/cm2 and 
0.54 to 0.88 % respectively. The formulations containing HPMC 
showed comparatively high hardness values of 7-8 kg/cm2
 
. This 
could be due to the presence of more fines in powder blend. Tablet 
hardness is not an absolute indicator of strength [18]. Another 
measure of a tablet’s strength is friability. Conventional compressed 
tablets that lose less than 1% of their weight are generally 
considered as acceptable. In the present study, the percentage 
friability for all the formulations was below 1%, indicating that the 
friability is within the prescribed limits [17]. All the formulations 
showed acceptable pharmacopeial properties for weight variation, 
drug content, hardness, and friability. 
Table 4: Evaluation of compressed tablets 
Formulation code Thickness a Weight variation  (mm) b Hardness  (mg) c (kg/cm2 Friability ) d Drug Content  (%) e (%) 
F1 5.5±2.15 251.08±2.65 6.5±2.12 0.75±2.12 98.20±2.12 
F2 5.4±2.12 245.11±2.23 7.5±2.23 0.88±2.02 100.96±2.12 
F3 5.6±2.08 249.23±2.12 6.5±2.04 0.85±2.02 98.37±2.03 
F4 5.4±2.14 253.18±2.22 6±2.03 0.76±2.05 98.92±2.12 
F5 5.4±2.62 254.28±2.06 6.5±2.15 0.72±2.11 101.55±2.12 
F6 5.6±2.32 255.07±2.30 7±2.15 0.73±2.12 99.54±2.13 
F7 5.3±2.02 252.12±2.65 6.5±2.08 0.68±2.54 98.36±2.13 
F8 5.4±2.16 250.06±2.92 7±2.06 0.61±2.45 99.96±2.12 
F9 5.3±2.09 252.15±2.68 7.5±2.12 0.88±2.16 98.03±2.26 
F10 5.5±2.28 253.22±2.34 8±2.11 0.62±2.28 98.54±2.16 
F11 5.4±2.23 252.26±2.08 7.5±2.09 0.65±2.12 100.99±2.12 
F12 5.6±2.18 248.19±2.16 7±2.12 0.75±2.11 99.01±2.12 
F13 5.5±2.15 251.24±2.34 8±2.07 0.73±2.04 100.64±2.15 
F14 5.4±2.15 255.09±2.35 7.5±2.16 0.64±2.12 99.32±2.15 
F15 5.3±2.17 247.29±2.18 7±2.32 0.58±2.32 99.54±2.13 
F16 5.4±2.13 254.08±2.63 8±2.24 0.69±2.41 99.69±2.12 
F17 5.6±2.16 252.09±2.02 7.5±2.26 0.73±2.15 98.06±2.12 
F18 5.3±2.19 248.24±2.32 7±2.54 0.65±2.02 99.10±2.15 
F19 5.5±2.36 250.05±2.12 7.5±2.02 0.72±2.68 98.89±2.11 
 a: mean±SD, n=3; b: mean±% deviation, n=20; c: mean±SD, n=5; d: Tablets equivalent to 6.5g; e: mean±SD, n=3 
 
The in vitro drug release characteristics were studied in phosphate 
buffer (pH 7.2) for a period of 12 h using USP type II dissolution 
apparatus (Disso 2000, Labindia). The formulation F1 to F4 
composed of eudragit RS 100 with 7.5%, 10%, 15%, 20% w/w. As 
the concentration of eudragit RS 100 increased the release was 
sustained. The formulation F3 & F4 showed drug release within 8 h 
& 9 h completely respectively.  
These formulations were further modified by using similar polymer 
category of another grade with same concentrations of eudragit RL 
100 (7.5%. 10%, 15%, 20% w/w). Formulation F5 released 90% 
drug at the end of 3 h. Formulation F6 and F7 completely drug 
release within 4 h and 6 h. The formulation F8 releases the drug 
slowly and complete up to the end of 12 h. We tried higher polymer 
concentration (25%, 30% w/w) indicated F9 and F10 to find out the 
drug release profile of ibuprofen, as the concentration was increased 
there was no release retardant for 12 h.  
The targeted release profiles parameters for tablet formulations 
were calculated as per Robinson and Erikson equation: after 1h, 30-
35% of the drug is released; after 6h, 60-65% of the drug is released; 
and finally, after 12 h; the remaining drug is released [19]. From the 
in vitro release profiles of formulation F8, it is evident that the 
prepared tablet exhibited release profile that fulfilled the above-
mentioned release requirement.  
Further, the formulae were modified by using another polymer 
which is hydrophilic i.e. HPMC with various grades like HPMC K15M, 
K4M and K100M with same concentrations (7.5%, 10% and 15%). 
The formulation F11, F14, F16, F17, F18 showed more than 90% 
drug release within 1 h because burst release of ibuprofen, but 
formulation F12 showed 100% drug release within 5h and F13 
showed within 7 h, due to its hydrophilic nature of the polymer. The 
formulation F19 showed 75% drug release in 1 h but showed 
complete drug release within 7 h. So all the formulations from F11 to 
F19 containing different grades of HPMC with various 
concentrations not showed the sustained drug release pattern.  
Among all the formulations containing eudragit (F1-F10) and HPMC 
(F11-F19), formula F8 (eudragit RL 100 with 20% w/w) showed 
better-sustained release pattern. Because eudragit RL has more 
ammonium groups are present as salts and make the polymers 
permeable. Eudragit reduced the drug release due to a reduction in 
the penetration of solvent molecule into the system. The rate of 
release was controlled by the permeability of matrix structure [20]. 
 
 
Fig. 2: In vitro dissolution profile of ibuprofen sustained release 
tablets with various concentrations of eudragit polymer 
(formula F1 to F10) 
Swain et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 2, 131-135 
135 
 
Fig. 3: In vitro dissolution profiles of ibuprofen sustained 
release tablets with various concentrations of HPMC polymer 
(formula F11 to F19) 
 
Characterization of drug releases kinetics 
In order to understand the kinetics and mechanism of drug release, 
the results of the in vitro drug release study were fitted into various 
kinetic models like zero order (cumulative percent drug released verses 
time), first order (log cumulative percentage drug retained verses time), 
Higuchi (cumulative percent released verses √T), and Peppas (log of 
cumulative percent released verses log time). The kinetic model that best 
fits the dissolution data was evaluated by comparing the coefficient of 
determination (r2
 




The hydrophilic matrix tablets of HPMC could not control the 
ibuprofen release effectively for 12 h. The matrix tablets containing 
eudragit RL 100 with 20% where found to be significantly effective 
in sustaining the drug release up to 12 h, is mainly due to the erosion 
process. It was concluded that eudragit RL can be used for the 
preparation of sustained release tablet of ibuprofen. It is evident 
from the results that a matrix tablet of ibuprofen is a better system 
for twice daily sustained release dosage regimen.  
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